OABI
Company Description
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 18.67M | 26.39M | 34.16M | 59.08M | 34.75M | 23.27M | 18.32M |
| Net Income | (64.78M) | (62.03M) | (50.62M) | (22.33M) | (27.04M) | (17.56M) | (13.59M) |
| EPS | -0.57 | -0.61 | -0.51 | -0.26 | -0.24 | -0.15 | -0.12 |
| Free Cash Flow | (37.02M) | (41.54M) | 703,000 | (20.75M) | (9.74M) | 1.87M | (5.45M) |
| FCF / Share | -0.33 | -0.41 | 0.01 | -0.24 | -0.08 | 0.02 | -0.05 |
| Operating CF | (36.45M) | (39.66M) | 2.35M | (3.59M) | (5.67M) | 3.62M | (5.20M) |
| Total Assets | 300.91M | 325.56M | 375.23M | 421.21M | 304.46M | 295.38M | 262.32M |
| Total Debt | 20.33M | 23.16M | 25.56M | 25.80M | 13.85M | 2.59M | 2.58M |
| Cash & Equiv | 25.52M | 27.60M | 16.36M | 33.39M | 0 | 0 | 0 |
| Book Value | 267.03M | 287.62M | 314.58M | 341.37M | 234.31M | 235.54M | 218.19M |
| Return on Equity | -0.24 | -0.22 | -0.16 | -0.07 | -0.12 | -0.07 | -0.06 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.41M | 14.40M | 8.38M | 2.24M | 3.90M | 4.15M | 10.80M | 4.17M | 7.61M | 3.80M | 4.82M | 5.48M |
| Net Income | (5.86M) | (7.70M) | (14.18M) | (16.52M) | (15.88M) | (18.20M) | (13.07M) | (16.37M) | (13.63M) | (18.96M) | (14.05M) | (15.74M) |
| EPS | -0.05 | -0.06 | -0.11 | -0.14 | -0.15 | -0.17 | -0.12 | -0.16 | -0.13 | -0.19 | -0.14 | -0.16 |
| Free Cash Flow | 2.57M | (5.08M) | (5.68M) | (9.95M) | (5.31M) | (16.08M) | (3.92M) | (6.73M) | (12.93M) | (17.96M) | (9.23M) | (6.69M) |
| FCF / Share | 0.02 | -0.04 | -0.04 | -0.09 | -0.05 | -0.15 | -0.04 | -0.07 | -0.13 | -0.18 | -0.09 | -0.07 |
| Operating CF | 2.68M | (4.91M) | (5.67M) | (9.76M) | (5.15M) | (15.87M) | (3.87M) | (6.58M) | (12.18M) | (17.03M) | (9.12M) | (6.20M) |
| Total Assets | 290.26M | 293.65M | 300.91M | 309.69M | 295.67M | 306.18M | 325.56M | 331.55M | 337.26M | 352.56M | 375.23M | 391.71M |
| Total Debt | 18.91M | 19.67M | 20.33M | 21.07M | 21.78M | 22.48M | 23.16M | 23.84M | 24.33M | 24.93M | 25.56M | 26.18M |
| Cash & Equiv | 24.34M | 29.05M | 25.52M | 28.54M | 18.28M | 10.89M | 27.60M | 27.24M | 20.79M | 19.06M | 16.36M | 21.25M |
| Book Value | 260.27M | 262.65M | 267.03M | 277.44M | 262.06M | 273.52M | 287.62M | 291.73M | 294.18M | 301.39M | 314.58M | 324.55M |
| Return on Equity | -0.02 | -0.03 | -0.05 | -0.06 | -0.06 | -0.07 | -0.05 | -0.06 | -0.05 | -0.06 | -0.04 | -0.05 |
